Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Rheumatology in Perspective · Olga Goodman, MD

Anti-SSA-negative disease and discordant tests

How to reconcile serology, biopsy and salivary gland ultrasound without overdiagnosis or premature exclusion.

Seronegativity is a laboratory description, not a single biological phenotype. When tests disagree, examine methods, tissue quality, the population in which accuracy was measured and the clinical decision still at stake.

Evidence checked: 2026-09-22 · UHFUS research-frontier update: 11 November 2026 · RheumaView original

Essentials

Use precise language. “SSA negative,” “SSA/SSB negative” and “ANA/RF/SSA/SSB negative” describe different groups. A paper calling a cohort seronegative may still include other autoantibodies, and a laboratory may report Ro52 separately from an SSA assay. Before interpreting prevalence or prognosis, check the operational definition. Chinese multicentre laboratory work illustrates substantial variation in how anti-SSA testing is performed and reported. [R06]

A negative SSA result can lower diagnostic probability without reducing it to zero. Positive minor salivary gland histology can support SjD when blood tests are negative, but neither biopsy nor serology replaces clinical correlation. Normal ultrasound is likewise one piece of evidence. The degree to which it changes the decision depends on the phenotype and the pre-test probability.

The central practical question is: What would resolving this disagreement change? Possible answers include diagnostic confidence, trial eligibility, investigation of an organ disorder or a decision to avoid another invasive test. These are distinct goals and may justify different next steps.

Clinical pathway: audit the evidence before adding tests
  1. Retrieve the original reports. Avoid decisions based only on “positive biopsy,” “negative autoimmune panel” or “normal scan.”
  2. Identify the mismatch. Is it between symptoms and function, function and structure, serology and histology, or one laboratory and another?
  3. Check quality and confounding. Examine collection conditions, assay targets, sample adequacy and the terminology used by the reader.
  4. Reconsider the phenotype. Is this uncomplicated sicca, an organ-first presentation, an overlap disorder or a focal gland problem?
  5. Choose the least burdensome informative action. Examples include expert review of existing slides, clarification from the laboratory or a targeted specialist assessment.
  6. Explain the remaining uncertainty. Record a follow-up trigger rather than an unsupported absolute conclusion.

This sequence is an original reasoning framework, not a validated decision rule. It is intended to reduce both diagnostic delay and the tendency to resolve ambiguity by accumulating unrelated tests.

Full review: the biopsy report that can answer the question

The relevant histological pattern is focal lymphocytic sialadenitis, interpreted in the appropriate tissue context. A focus score is meaningful only after the pattern and sample quality have been assessed. “Chronic inflammation” does not automatically mean SjD; nonspecific chronic sialadenitis, atrophy, fibrosis and ductal changes require careful interpretation. International standardisation guidance addresses tissue acquisition, glandular area, the definition of a focus and reporting. Its procedural recommendations are consensus based, with limitations in the underlying evidence. [R03]

Ask the pathology service whether the specimen was adequate, whether focal lymphocytic sialadenitis was present, what glandular area was evaluated, how the focus score was calculated and whether background changes complicated interpretation. If the report is ambiguous, review by a pathologist experienced in salivary gland disease may be more useful than immediately repeating the procedure. Review does not guarantee a different answer; it improves the reliability of the answer already available.

Biopsy has burdens as well as diagnostic value. Discuss pain, bleeding, local sensory disturbance and the possibility of an inconclusive result, using the performing service’s experience. A US procedural cohort reported sample adequacy and complications, but a single-centre estimate is not a universal complication rate. Biopsy should answer a defined question that matters to the patient. [R11]

Focus score: the denominator and tissue context matter

A focus is a cluster of at least 50 mononuclear cells in the appropriate histological setting; the score expresses the number of qualifying foci per 4 mm² of glandular tissue. Consider a purely arithmetic illustration: two qualifying foci in 8 mm² give a score of 1; one focus in the same area gives 0.5. Neither number can be interpreted responsibly without first confirming the pattern and the tissue denominator. A report of a cluster near extensive duct damage is not automatically equivalent to focal lymphocytic sialadenitis in otherwise preserved tissue. [R03]

When an apparently decisive score comes from a very small sample, the finding may be less robust than its decimal precision suggests. The international standardisation paper recommends adequate gland number and tissue area and addresses deeper levels when needed. These are methods intended to improve reliability; they do not eliminate sampling variability. Ask for the denominator and adequacy assessment before assigning confidence.

Keep three outputs separate: the diagnostic inflammatory pattern; other pathology that explains the gland abnormality; and possible prognostic features. A high score or an organised lymphoid aggregate is not, by itself, a lymphoma diagnosis. Suspicion of lymphoma requires the appropriate lesion-directed and haematopathological assessment.

Full review: what a normal ultrasound can and cannot do

Salivary gland ultrasound examines the structure of major glands; a labial biopsy samples minor glands. They do not interrogate identical tissue or biology. Ultrasound can help characterise diffuse change and identify a focal abnormality. Operator experience, the scoring method and the disease spectrum influence its diagnostic performance. It is not part of the original 2016 ACR/EULAR classification score. [R02] [R04]

In a French sicca-clinic study, a normal ultrasound in SSA-negative patients had a reported negative predictive value of 92%. This is useful evidence for selected patients in a similar setting. It is not a promise that every SSA-negative person with a normal scan has only an 8% chance of SjD: predictive values depend on prevalence and selection. Nor does it establish that biopsy can always be omitted in a patient referred for otherwise unexplained neurological or pulmonary disease. [R04]

An appropriate discussion is conditional: if clinical suspicion is low after a complete assessment, a reassuring scan may support observation; if substantial unexplained objective disease remains, reconsider what further evidence would change management. Neither pathway should be presented as an automatic consequence of the scan alone.

Why a reassuring negative predictive value can mislead

Predictive value incorporates the prevalence of disease in the tested population. Here is an intentionally hypothetical illustration, not the performance of a SjD test: a test with 50% sensitivity and 90% specificity would have a negative predictive value of about 94% when disease prevalence is 10%, but about 73% when prevalence is 40%. The test has not changed; the population has. These figures are calculated from the stated assumptions and are not individual risk estimates.

This is why a sicca-clinic ultrasound result should not be transplanted uncritically into a referral population with neuropathy or interstitial lung disease. Evaluate the likelihood contribution of the result alongside the clinical phenotype, not the published negative predictive value in isolation. A test with limited sensitivity can generate many reassuring negatives in a low-prevalence setting while still missing a clinically important fraction of affected patients.

Further testing is justified when the expected information can resolve a material decision. It is not justified merely to force every uncertain case into a binary label. The threshold for investigating possible organ-threatening disease differs from the threshold for clarifying stable isolated dryness.

Discordance matrix
PatternInterpretation to testUseful next question
SSA negative; convincing gland dysfunctionSeronegative SjD remains possible; non-autoimmune causes also remain possible.Would expert histology meaningfully resolve the diagnosis?
SSA positive; limited objective gland evidenceAntibody positivity may precede gland disease or relate to another autoimmune context.What phenotype is actually present, and what follow-up is justified?
Qualifying biopsy; normal ultrasoundDifferent glands and different measurements may explain the mismatch.Are both reports technically credible, and is there complementary objective evidence?
Abnormal ultrasound; negative biopsySampling, morphology, nonspecific structural change or another gland disorder may contribute.Is expert review or evaluation of a focal lesion needed?
Severe dryness; near-normal measured secretionSymptoms and secretion are not equivalent; ocular surface, oral, sensory or medication factors may coexist.Which treatable mechanism best explains the patient’s impairment?
Systemic presentation; negative routine gland testsThe systemic disorder needs its own differential; SjD attribution remains open.What organ-specific evidence and alternatives should be assessed next?

This matrix is an editorial synthesis, not a hierarchy that assigns automatic priority to one test. It intentionally leaves room for more than one process in the same patient.

Complex questions: is seronegative disease necessarily milder?

No single prognostic statement applies to every seronegative group. A 2024 Chinese retrospective cohort described a phenotype with greater emphasis on exocrine manifestations and less systemic or B-cell-related activity. Another Chinese study of 934 patients reported substantial interstitial lung disease in its antibody-negative group. Those results should not be averaged into a reassuring or alarming universal percentage. [R07] [R08]

The cohorts differed in recruitment, definitions and ascertainment. In the larger study, antibody-negative cases had positive lip biopsies; the group therefore does not represent all people with negative antibodies and dryness. Some patients were separately Ro52 positive despite the study’s SSA/SSB-negative definition. Referral enrichment and assay terminology can materially change the apparent phenotype. These observations argue for closer reading of the methods, not for assigning prognosis by continent. [R08]

A US neurological referral cohort also documented seronegative, biopsy-positive disease. Such a cohort demonstrates that clinically important neurological presentations can occur, but cannot estimate their frequency in an unselected SjD population. Assess the individual organ phenotype rather than treating seronegativity as a certificate of low risk. [R12]

Complex questions: should serology be repeated?

First establish whether the original test addressed the intended question. A negative screening test, an assay limited to particular antigens and a full report that explicitly describes Ro52/Ro60 are not interchangeable documents. Comparative assay studies demonstrate variation in detection. Consultation with the laboratory or a different validated method may be reasonable when a strong clinical discordance remains; indiscriminate repetition is less informative. [R06] [R13]

Do not tell a patient that their antibodies will necessarily become positive later. Longitudinal studies observe group-level trajectories, not an inevitable sequence for every individual. A review is more defensible when new objective findings emerge, an earlier result is technically questionable or the answer would change a concrete decision. [R10]

When discussing an unexpected positive result, explain that a laboratory signal requires context. It does not establish the activity of SjD, justify immunosuppression for nonspecific symptoms or establish autoimmune causation of an unrelated organ problem.

Research frontier: early antibodies and non-invasive diagnosis

Antibodies to SP1, CA6 and PSP have been studied as potential markers, including in Chinese cohorts and US paediatric and neurological populations. The term “early Sjögren panel” should not be read as proof that a positive result identifies a validated early disease stage. Study designs, comparator groups and assay definitions vary. A positive exploratory marker does not by itself establish SjD or replace established clinical evaluation. [R14] [R26] [R27]

Other novel autoantibody combinations have been investigated in SSA-negative disease with external validation work. This is a meaningful research direction, but discovery, validation in selected cohorts and demonstrated utility in routine practice are separate steps. A useful future marker must improve decisions, not simply distinguish already well-characterised cases from controls. [R28]

Labial-gland ultra-high frequency ultrasound (UHFUS): a single-centre study published on 3 July 2026 examined 270 people with suspected SjD (136 classified as SjD, 134 with sicca). A grey-scale score ≥2 had 66.2% sensitivity and 84.3% specificity. The reported AUC of 0.945 belongs to an exploratory modification of the ACR/EULAR classification score that replaced biopsy with one UHFUS point; it is not the standalone accuracy of routine major-gland ultrasound. Data-driven cut-offs and the absence of independent multicentre validation limit generalisation. This is a research direction for selected specialist settings, not a revision of the 2016 criteria or a general reason to omit biopsy in anti-SSA-negative patients. [R71]

For any proposed replacement for biopsy, ask five questions: was the study prospective; were diagnostically difficult controls included; was the reference assessment independent; was performance replicated outside the development centre; and did use of the test improve patient-important decisions? These are proposed appraisal questions. They are not an endorsement of a commercial panel or a claim that a particular emerging technology has completed that pathway.

Biopsy for SjD versus biopsy for a focal gland lesion

A lip biopsy asks whether sampled minor glands show a relevant inflammatory pattern. A persistent focal parotid lesion asks whether that lesion represents obstruction, another inflammatory disorder or neoplasia. A normal lip biopsy cannot exclude lymphoma in a different, unsampled site. The BSR guideline recommends early investigation of new gland swelling or other findings suggesting lymphoma. [R47]

Ultrasound-guided core needle sampling can provide architecture and material for ancillary studies in experienced hands. Recent primary work examines its feasibility and tissue adequacy. That supports a specialist diagnostic option, not routine core biopsy of everyone with SjD. The choice between imaging, core sampling, surgical biopsy and other investigation depends on the lesion and the expertise available. [R60]

An isolated clonal result also requires interpretation within the morphology and clinical setting. “Clonal,” “high focus score,” “germinal-centre-like structure” and “lymphoma” should never become interchangeable labels in a patient-facing explanation.

The diagnosis does not specify the treatment target

Positive histology can support SjD without establishing that fatigue, diffuse pain or every neurological symptom reflects treatment-responsive immune inflammation. Conversely, low systemic activity does not make symptom burden unimportant. Observational stratification work identifies differing symptom patterns and biological associations, but those groups are not a validated prescription algorithm. [R53]

A mechanistic change is also not synonymous with symptomatic benefit. Analyses of JOQUER samples found effects on interferon-related activity; subsequent symptom-stratified reanalyses generated hypotheses about differential response. These findings require prospective testing and should not reverse the interpretation of a negative primary clinical trial by selective subgroup reading. [R69] [R70]

For emerging therapies, check which patients were enrolled. Evidence from a population selected for particular antibodies or systemic activity may not transfer directly to biopsy-positive, SSA-negative disease with low measured systemic activity. Describe that applicability gap explicitly; lack of direct evidence is different from evidence of no possible effect. Trial participation and treatment decisions require more than meeting classification criteria.

Explaining an unresolved assessment to the patient

A practical formulation is: “Your symptoms and findings deserve treatment. The current evidence does not yet give a secure explanation for all of them. The negative blood test reduces one type of evidence; it does not erase the other findings. The next investigation is intended to answer a specific question, and we will discuss whether its likely benefit justifies its burden.”

If a diagnosis is supported despite negative antibodies, explain the positive evidence that supports it. If it is not supported, explain which alternatives remain and how symptoms will still be addressed. Avoid framing uncertainty as a choice between dismissing the patient and assigning a definitive autoimmune label.

For follow-up, agree what should prompt earlier review: a new objectively documented organ finding, persistent or changing gland enlargement, a substantial change in function or another specific concern identified during the consultation. The interval and investigations should follow the person’s findings and risks, rather than an automatic schedule of repeated biopsy or antibody panels.

Evidence and next reading

Read the companion diagnostic pathway for the initial assessment and the patient explanation for accessible language. The evidence here combines international consensus methods with primary European, US and Chinese cohort studies. It does not constitute a globally exhaustive review of seronegative disease.

What remains unresolved: the optimal pathway for every SSA-negative phenotype; when a normal ultrasound can safely avoid biopsy outside selected sicca populations; how to define clinically useful seronegative endotypes; and whether new biomarkers can improve decisions without increasing false-positive diagnoses. These are active questions, not established clinical claims.

Sources

  1. R02 2016 ACR/EULAR classification criteria for primary Sjögren’s syndrome
    Original classification study
  2. R03 Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren’s syndrome (2017)
    International methods consensus
  3. R04 Normal salivary gland ultrasonography in anti-SSA-negative patients with sicca (2021)
    France; primary diagnostic cohort
  4. R06 Current state of technologies and recognition of anti-SSA/Ro antibodies in China (2021)
    China; multicentre laboratory study
  5. R07 Seronegative primary Sjögren’s syndrome, a distinct subtype (2024)
    China; retrospective cohort
  6. R08 Antibody-negative phenotype in a Chinese cohort of 934 patients
    China; retrospective single-centre cohort
  7. R10 Natural history and predictors of progression in the SICCA registry (2018)
    International longitudinal cohort
  8. R11 Minor salivary gland biopsy in diagnosis of Sjögren’s syndrome (2022)
    US; procedural cohort
  9. R12 Neurologic involvement in seronegative, biopsy-positive primary Sjögren’s syndrome (2023)
    US; neurological referral cohort
  10. R13 Comparison of anti-Ro52, anti-Ro60 and anti-La immunoassays (2016)
    Primary assay comparison
  11. R14 Diagnostic performance of early Sjögren autoantibodies in a juvenile cohort (2021)
    US; primary paediatric cohort
  12. R26 Tissue-specific autoantibodies in early primary Sjögren’s syndrome (2019)
    China; primary biomarker study
  13. R27 Early Sjögren antibody panel in sensory neuropathy (2026)
    Primary exploratory study
  14. R28 Novel autoantibodies in anti-SSA-negative Sjögren disease (2024)
    Primary biomarker and validation study
  15. R47 BSR guideline on adult and juvenile onset Sjögren disease (online 2024; issue 2025)
    UK; multidisciplinary guideline
  16. R53 Symptom-based stratification of international Sjögren cohorts (2019)
    Primary cohort analysis and trial reanalysis
  17. R60 Ultrasound-guided parotid core biopsy in Sjögren disease (2025)
    Primary procedural and tissue-adequacy study
  18. R69 Hydroxychloroquine and interferon activation in JOQUER (2020)
    Primary mechanistic analysis of trial samples
  19. R70 Revisiting JOQUER through symptom stratification (2021)
    Post hoc trial reanalysis; hypothesis generating
  20. R71 Fulvio et al. Ultra-high frequency ultrasound of labial salivary glands in Sjögren’s disease: diagnostic accuracy and patient stratification (2026)
    RMD Open 12:e006906 · Single-centre diagnostic classification study · Published 3 July 2026

↑ All articles

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Diagnostic evidenceSeronegative diseaseSjögren disease